IL194775A - Medicinal products containing anti-secretory protein for use in the treatment of dysfunction of floating fat rafts and / or kowala and / or its prevention - Google Patents

Medicinal products containing anti-secretory protein for use in the treatment of dysfunction of floating fat rafts and / or kowala and / or its prevention

Info

Publication number
IL194775A
IL194775A IL194775A IL19477508A IL194775A IL 194775 A IL194775 A IL 194775A IL 194775 A IL194775 A IL 194775A IL 19477508 A IL19477508 A IL 19477508A IL 194775 A IL194775 A IL 194775A
Authority
IL
Israel
Prior art keywords
caveolae
dysfunction
prevention
treatment
pharmaceutical compositions
Prior art date
Application number
IL194775A
Other languages
English (en)
Hebrew (he)
Other versions
IL194775A0 (en
Original Assignee
Lantmannen As Faktor Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantmannen As Faktor Ab filed Critical Lantmannen As Faktor Ab
Publication of IL194775A0 publication Critical patent/IL194775A0/en
Publication of IL194775A publication Critical patent/IL194775A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
IL194775A 2006-04-27 2008-10-22 Medicinal products containing anti-secretory protein for use in the treatment of dysfunction of floating fat rafts and / or kowala and / or its prevention IL194775A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0600933 2006-04-27
US92082607P 2007-03-30 2007-03-30
PCT/SE2007/000415 WO2007126365A2 (en) 2006-04-27 2007-04-27 Further medical uses of antisecretory protein

Publications (2)

Publication Number Publication Date
IL194775A0 IL194775A0 (en) 2011-08-01
IL194775A true IL194775A (en) 2015-09-24

Family

ID=38655930

Family Applications (1)

Application Number Title Priority Date Filing Date
IL194775A IL194775A (en) 2006-04-27 2008-10-22 Medicinal products containing anti-secretory protein for use in the treatment of dysfunction of floating fat rafts and / or kowala and / or its prevention

Country Status (10)

Country Link
US (1) US8487074B2 (enExample)
EP (1) EP2037950B1 (enExample)
JP (2) JP5508846B2 (enExample)
KR (1) KR20090037992A (enExample)
AU (1) AU2007244005B2 (enExample)
CA (1) CA2650132C (enExample)
IL (1) IL194775A (enExample)
MX (1) MX2008013777A (enExample)
PL (1) PL2037950T3 (enExample)
WO (1) WO2007126365A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG171602A1 (en) * 2006-04-27 2011-06-29 Lantmaennen As Faktor Ab Use of antisecretory factors for treating intraocular hypertension
KR20090037992A (ko) 2006-04-27 2009-04-17 란트만넨 아스-팍토르 아베 항분비 단백질의 추가적 의학 용도
PL2040734T3 (pl) 2006-04-27 2012-04-30 Lantmaennen As Faktor Ab Białko przeciwwydzielnicze do zastosowania w leczeniu zespołu przedziału
US9962424B2 (en) 2007-04-27 2018-05-08 Lantmännen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
US8901083B2 (en) 2008-11-25 2014-12-02 Temple University Administration of angiocidin for the treatment of leukemia
JP5820277B2 (ja) 2009-02-11 2015-11-24 ラントメネン・アーエス−ファクトール・アーベー 細胞取込を最適化するための抗分泌性因子（ａｆ）の使用
WO2017009004A1 (en) 2015-07-10 2017-01-19 Lantmännen As-Faktor Ab Process for producing egg yolk with high content of af-16
US11407796B2 (en) 2016-07-18 2022-08-09 Lantmännen As-Faktor Ab Antisecretory factor 17
WO2020002464A1 (en) 2018-06-28 2020-01-02 Lantmännen Medical Ab Antisecretory factor for use in treatment and/or prevention of acute respiratory failure
WO2022159845A1 (en) * 2021-01-22 2022-07-28 University Of Virginia Patent Foudation Altering protein function by pharmacological targeting of membrane domains

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585401A (en) 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
SE508609C2 (sv) 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
WO1997027296A1 (en) * 1996-01-26 1997-07-31 Hsc Research And Development Limited Partnership Nucleic acids and proteins related to alzheimer's disease, and uses therefor
SE9604251L (sv) 1996-11-20 1997-12-22 Svenska Lantmaennen Riksfoerbu Födoämne som vid förtäring inducerar antisekretoriska proteiner
SE513496C2 (sv) 1998-12-17 2000-09-18 Rural Patent Svenska Ab NASP-berikad äggula samt dess användning
GB0322645D0 (en) * 2003-09-26 2003-10-29 Melacure Therapeutics Ab Use of antisecretory factor peptides
KR20090037992A (ko) 2006-04-27 2009-04-17 란트만넨 아스-팍토르 아베 항분비 단백질의 추가적 의학 용도
PL2040734T3 (pl) * 2006-04-27 2012-04-30 Lantmaennen As Faktor Ab Białko przeciwwydzielnicze do zastosowania w leczeniu zespołu przedziału
EP2682819A2 (en) * 2012-07-04 2014-01-08 Xeikon IP B.V. A method for forming a multi-colour image

Also Published As

Publication number Publication date
US20090149382A1 (en) 2009-06-11
MX2008013777A (es) 2009-02-03
KR20090037992A (ko) 2009-04-17
WO2007126365A2 (en) 2007-11-08
EP2037950B1 (en) 2014-04-23
JP5508846B2 (ja) 2014-06-04
AU2007244005A1 (en) 2007-11-08
PL2037950T3 (pl) 2014-09-30
IL194775A0 (en) 2011-08-01
HK1128237A1 (en) 2009-10-23
WO2007126365A8 (en) 2009-03-05
JP2009535330A (ja) 2009-10-01
JP2014111623A (ja) 2014-06-19
EP2037950A2 (en) 2009-03-25
CA2650132C (en) 2017-10-24
US8487074B2 (en) 2013-07-16
WO2007126365A3 (en) 2008-03-13
JP6063401B2 (ja) 2017-01-18
AU2007244005B2 (en) 2012-08-02
CA2650132A1 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
ZA200900388B (en) Compositions and methods for the treatment of mucositis
IL199045A0 (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
SI2079760T1 (sl) Sestavki in metode za zdravljenje okužb
GB0412753D0 (en) Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis
EP1993540A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS
EP1940361A4 (en) PHARMACEUTICAL DOSAGE FORMS HAVING CONTROLLED AND / OR IMMEDIATE RELEASE PROPERTIES
ZA200801706B (en) Methods and compositions for the prevention and treatment of kidney disease
LT1965816T (lt) Farmacinės kompozicijos ir metodai, skirti su oksalatu susijusių ligų gydymui arba prevencijai
PL1794174T3 (pl) Sposoby i kompozycje do hamowania wrodzonych odpowiedzi immunologicznych i autoodporności
IL197148A0 (en) Methods and compositions for the treatment of antibody mediated neuropathies
IL198847A (en) Process for making 2-imino-thiazolidine-4-on and several such histories
ZA200808431B (en) Fungicidal compositions and methods of using the same
BRPI0720124A2 (pt) Composições farmacêuticas e seus métodos de uso.
ZA200800448B (en) Methods and compositions for the prevention and treatment of inflammatory disease
EP1966246A4 (en) METHOD AND COMPOSITIONS FOR NEEDLE-FREE ADMINISTRATION OF ANTIBODIES
EP1896070A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF RENAL DISEASE
EP1874130A4 (en) METHOD AND COMPOSITIONS FOR PREVENTING AND TREATING NURSE DISEASES
ZA200707955B (en) Methods and pharmaceutical compositions for the treatment of neurological damage
IL197236A (en) Pharmaceuticals containing Almatosumab and uses of Almatosumab for the preparation of pharmaceuticals to reduce the risk of MS
PT1938684E (pt) Utilização de polioximetilenodialquiléteres e/ou de acetais de dialdeído para a preservação de corpos humanos ou animais, e composições contendo-os
EP2005964A4 (en) MEDICAMENT FOR TREATING HYPERPHOSPHATEEMIA AND PREPARATION METHOD THEREOF
GB0614365D0 (en) Pharmaceutical compositions and their use
ZA200900231B (en) (S)-(-)-amlodipine camsylate or hydrate thereof and pharmaceutical composition comprising same
IL189827A0 (en) Pharmaceutical dosage forms and compositions comprising lecoztan
PT2474528E (pt) Compostos antineoplásicos e composições farmacêuticas dos mesmos

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed